Patents by Inventor Kaixian Chen

Kaixian Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140323466
    Abstract: Disclosed are new thienyl[3,2-d]pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes.
    Type: Application
    Filed: October 23, 2012
    Publication date: October 30, 2014
    Inventors: Hong Liu, Jia Li, Jian Li, Jingya Li, Jiang Wang, Mingbo Su, Jie Lian, Hualiang Jiang, Kaixian Chen
  • Publication number: 20140235877
    Abstract: The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Zhengxiang XIA, Yuanzhi LAO, Hongsheng TAN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Kaixian CHEN, Albert Sun-Chi CHAN
  • Publication number: 20140200265
    Abstract: This invention relates to the use of a natural compound from natural sources for its therapeutic uses. More particularly, it relates to a compound 1,3,5,7-tetrahydroxy-8-isoprenylxanthone (TI, FIG. 1), that is naturally occurring in the plant of Garcinia esculenta Y. H. Li, and its biological activity of inhibiting nitric oxide production and microRNA 155 expression in stimulated macrophages, which can be developed as potential anti-inflammatory drugs.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 17, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi Xu, Dandan Zhang, Hong Zhang, Kaixian Chen, Zhaoxiang Bian, Chengyuan Lin, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20140194528
    Abstract: The present invention relates to a synthetic compound and its therapeutic uses.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Yunhui SHEN, Yuanzhi LAO, Kaixian CHEN, Dajian YANG, Shilin CHEN, Zhaoxiang BIAN, Aiping LU, Albert Sun Chi CHAN, Chengyuan LIN
  • Publication number: 20140194498
    Abstract: A novel polyisoprenylated tetracyclic xanthone, named garciesculentone B, isolated from Garcinia esculenta Y. H. Li is disclosed in the present invention. This compound is shown to have significant cytotoxicity against various cancer cells. In addition, garciesculentone B is shown to have antimigration effect on various cancer cells such as human esophageal carcinoma cell. The experimental data supports that this compound is useful for developing into an anticancer drug.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Hong ZHANG, Zhichao XI, Hongsheng TAN, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140194529
    Abstract: This invention relates to the use of a compound from natural sources for therapeutic uses. More particularly, it relates to a compound, Garcimultiflorone E, naturally occurring in the plant of Garcinia esculenta Y. H. Li which has potent anti-inflammation and anti-cancer effect.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Dandan ZHANG, Hong ZHANG, Kaixian CHEN, Zhaoxiang BIAN, Chengyuan LIN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140194499
    Abstract: Two novel polyprenylated benzoylphloroglucinol derivatives, garciesculentones A and C, are disclosed in the present invention. Garciesculentones A and C exhibit cytotoxicity and/or antimigration effect against various cancer cell lines. The experimental results of the present invention suggest that Garciesculentones A and C are useful for developing into anticancer drugs.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Hong ZHANG, Yuanzhi LAO, Dandan ZHANG, Kaixian CHEN, Zhaoxiang BIAN, Chengyuan LIN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140194530
    Abstract: Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising Garcinia species such as Garcinia yunnanesis Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition of cancer metastasis and inhibition of autophagic flux.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi Xu, Yuanzhi Lao, Hongsheng Tan, Naihan Xu, Xiaoyu Wang, Zhenyan Liu, Kaixian Chen, Zhaoxiang Bian, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20140088130
    Abstract: The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong LIU, Xin XIE, Xuechu ZHEN, Haifeng SUN, Jing LI, Liyuan ZHU, Zeng LI, Ying CHEN, Hualiang JIANG, Kaixian CHEN
  • Patent number: 7662860
    Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: February 16, 2010
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Lead Discovery Pharmaceuticals Limited Company
    Inventors: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye
  • Publication number: 20090182133
    Abstract: The invention relates to pharmaceutical compositions comprising benzopyranone derivatives for the treatment of Severe Acute Respiratory Syndrome (SARS).
    Type: Application
    Filed: December 15, 2006
    Publication date: July 16, 2009
    Inventors: Chum Mok Puah, Weiliang Zhu, Jian Li, Lili Chen, Cheng Luo, Gang Chen, Zhili Zuo, Xiaomin Luo, Xu Shen, Kaixian Chen, Hualiang Jiang
  • Patent number: 7456205
    Abstract: The invention relates to the benzopyran compounds of formula (I), or the salts thereof, in which, the bond between 3 and 4 positions is a single or double bond; R1 represents a hydrogen atom or a C1-6 alkyl that can be substituted; R2 represents a hydrogen atom, a C1-6 alkyl that can be substituted or an aromatic carbocyclic or aromatic heterocyclic group that can be substituted. The invention also relates to a process for preparing such compounds or their salts as well as the use of such compounds or their salts in the preparation of the medicine against type II diabetes mellitus.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: November 25, 2008
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Yushe Yang, Lei Tang, Ruyun Ji, Kaixian Chen
  • Publication number: 20060178405
    Abstract: The invention relates to the benzopyran compounds of formula (I), or the salts thereof, in which, the bond between 3 and 4 positions is a single or double bond; R1 represents a hydrogen atom or a C1-6 alkyl that can be substituted; R2 represents a hydrogen atom, a C1-6 alkyl that can be substituted or an aromatic carbocyclic or aromatic heterocyclic group that can be substituted. The invention also relates to a process for preparing such compounds or their salts as well as the use of such compounds or their salts in the preparation of the medicine against type II diabetes mellitus.
    Type: Application
    Filed: February 26, 2003
    Publication date: August 10, 2006
    Inventors: Yushe Yang, Lei Tang, Ruyun Ji, Kaixian Chen
  • Publication number: 20060154970
    Abstract: The present invention provides alanines compounds of formula (I) or their salts: In the formula (I), the configuration of ?-Carbon atom of alanine is R or S; R1 is hydrogen, unsubstituted or substituted C1-6alkyl, unsubstituted or substituted aryl or aromatic heterocyclic group; R2 is hydrogen or unsubstituted or substituted C1-6 alkyl. The present invention also provides two methods of preparing these compounds or their salts, and their use in preparing anti II type diabetic medicine.
    Type: Application
    Filed: January 28, 2003
    Publication date: July 13, 2006
    Inventors: Yushe Yang, Lei Tang, Ruyun Ji, Kaixian Chen
  • Publication number: 20060142383
    Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.
    Type: Application
    Filed: December 2, 2005
    Publication date: June 29, 2006
    Inventors: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye